Fig. 3: Effects of dapagliflozin on selected secondary endpoints and in supportive responder analysis. | Nature Medicine

Fig. 3: Effects of dapagliflozin on selected secondary endpoints and in supportive responder analysis.

From: The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

Fig. 3

a–c, Effects of dapagliflozin on selected secondary endpoints and in supportive responder analysis. Effects of dapagliflozin versus placebo at 12 weeks on 6MWT distance (a), KCCQ-CS responder analysis (b) and KCCQ-OS (c). Data are presented as mean values with 95% CI. a,c, An F-test was used in data analysis; b, a chi-square test was used in data analysis All P values are two-sided, with no adjustments made for multiple comparisons.

Back to article page